PARP7-IN-22 (XLY-1) (Male rats, 5 mg/kg, i.v.; 30 mg/kg, p.o; 0.5-24 h) can be administered orally for further in vivo pharmacodynamic studies[1].PARP7-IN-22 (CT26 syngeneic model, 25 or 50 mg/kg, p.o., 14 days) demonstrates excellent anti-tumor proliferative effects in the CT26 syngeneic model [1].PARP7-IN-22 (CT26 syngeneic model, 50 mg/kg, p.o., 14 days) promotes T cell infiltration into tumor tissues and exhibits targeted effects[1].
1.19
Pharmacokinetic Analysis in CT26 Syngeneic Model[1]|
| PARP7-IN-22 (XLY-1) | T1/2 (h) | Tmax (h) | Cmax(g/mL) | C0(g/mL) | AUC0-∞ (h ng/mL) | Vz (L/kg) | CL (L/h/kg) | MRT0-∞(h) | F (%) |
| i.v. (5 mg/kg) | 5.42 | 1.25 | 353.80 | 1632.80 | 1626.00 | 0.029 | 0.004 | 3.22 | - |
| p.o. (30 mg/kg) | 5.52 | 1.75 | 674.00 | - | 2368.10 | 0.112 | 0.014 | 4.84 | 24.27 |
